Erector Spinae Block vs. Placebo Block Study
Launched by WOMEN'S COLLEGE HOSPITAL · Jun 5, 2019
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a method called the Erector Spinae Block, which is a type of nerve block used during breast cancer surgery. The goal is to see if this technique can help patients manage pain better after surgery compared to a placebo, which is a fake treatment. Using nerve blocks can reduce reliance on stronger pain medications, leading to less nausea and quicker recovery times for patients.
To participate in this trial, patients need to be between the ages of 18 and 75 and have a body mass index (BMI) under 35. They should be scheduled for a same-day surgery and must not have had previous major breast surgery or certain medical conditions that could complicate treatment. Participants will receive either the Erector Spinae Block or the placebo during their surgery and be monitored for how well they manage pain afterward. It's important for anyone considering this trial to understand the criteria and talk to their doctor to see if they qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ASA classification: I-III
- • BMI \< 35 kg/m2
- • Day surgery procedure
- Exclusion Criteria:
- • Prior ipsilateral breast surgery, excluding lumpectomy
- • Pre-existing neurological deficit or peripheral neuropathy involving the ipsilateral chest
- • Severe, poorly controlled cardiac conditions, significant arrhythmias, severe valvular heart diseases
- • Severe, poorly controlled respiratory conditions (severe COPD, severe interstitial lung disease, severe / poorly controlled asthma)
- • Contraindication to regional anaesthesia (e.g. bleeding diathesis, coagulopathy, sepsis, infection at the site of potential needle puncture on the posterior chest)
- • Patient refusal
- • Chronic pain disorder
- • Chronic opioid use (≥30 mg oxycodone / day)
- • Contraindication (or allergy) to a component of multi-modal analgesia protocol
- • Allergy to amide local anaesthetics used in nerve blocks
- • Contraindications to any of the components of the standardized general anaesthesia
- • Significant psychiatric disorder that would preclude objective study assessment
- • Pregnancy/ women with nursing infants
- • Unable to provide informed consent
- • Unable to speak and read English
About Women's College Hospital
Women's College Hospital (WCH) is a leading academic health sciences center in Toronto, dedicated to advancing women's health through innovative research, education, and exceptional patient care. As a progressive institution, WCH focuses on addressing the unique health needs of women, fostering groundbreaking clinical trials that contribute to the understanding and treatment of various health conditions. With a commitment to collaboration, WCH partners with various stakeholders, including academic institutions and healthcare organizations, to enhance the quality of care and improve health outcomes for women. Through its robust research programs, Women's College Hospital is at the forefront of shaping future healthcare practices and policies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Richard Brull, MD,FRCPC
Principal Investigator
Women's College Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials